Lifileucel
- Generic Name
- Lifileucel
- Drug Type
- Biotech
- CAS Number
- 2306267-74-1
- Unique Ingredient Identifier
- R0835E18NH
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Conditions
- Melanoma, Cutaneous Malignant
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06743126
- Locations
- 🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸UCLA Hematology/Oncology, Los Angeles, California, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06481592
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Hospital, Detroit, Michigan, United States
🇺🇸University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸MD Anderson Cancer Center - U of Texas, Houston, Texas, United States
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC
- Conditions
- Non Small Cell Lung Cancer MetastaticNon Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Shanghai Juncell Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT06473961
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Efficacy & Safety for LN144 with Pembrolizumab with High Risk Stage IIIb-dResectable Melanoma
- Conditions
- Stage IIID MelanomaStage IIIB MelanomaStage IIIC Melanoma
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- James Isaacs, MD
- Target Recruit Count
- 12
- Registration Number
- NCT06190249
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
- Conditions
- Uveal MelanomaMetastatic Cutaneous Melanoma
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 6
- Registration Number
- NCT05903937
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Conditions
- MelanomaUnresectable MelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 670
- Registration Number
- NCT05727904
- Locations
- 🇺🇸
University of Alabama at Birmingham: The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study of LN-144 in People With Metastatic Melanoma to the Brain
- Conditions
- Metastatic Melanoma
- Interventions
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT05640193
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
- Conditions
- Uveal MelanomaMelanomaMetastatic MelanomaMetastatic Uveal Melanoma
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05607095
- Locations
- 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
- Conditions
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Stage IV MelanomaLocally Advanced MelanomaPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- Procedure: Therapeutic Conventional Surgery
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Richard Wu
- Target Recruit Count
- 2
- Registration Number
- NCT05176470
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
- Conditions
- Metastatic Uveal MelanomaMetastatic Cutaneous Melanoma
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 6
- Registration Number
- NCT04812470
- Locations
- 🇸🇪
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.